AR011409A1 - Derivados de 16-hidroxi-11-(fenil substituido)-estra-4,9-dieno, su utilizacion, un procedimiento para prepararlos, formulaciones farmaceuticasque comprenden a dichos derivados, y un compuesto utilizable como intermediario para prepararlos - Google Patents
Derivados de 16-hidroxi-11-(fenil substituido)-estra-4,9-dieno, su utilizacion, un procedimiento para prepararlos, formulaciones farmaceuticasque comprenden a dichos derivados, y un compuesto utilizable como intermediario para prepararlosInfo
- Publication number
- AR011409A1 AR011409A1 ARP980100151A ARP980100151A AR011409A1 AR 011409 A1 AR011409 A1 AR 011409A1 AR P980100151 A ARP980100151 A AR P980100151A AR P980100151 A ARP980100151 A AR P980100151A AR 011409 A1 AR011409 A1 AR 011409A1
- Authority
- AR
- Argentina
- Prior art keywords
- derivatives
- prepare
- 6alkyl
- oxo
- estra
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- -1 16-hydroxy-11- (substituted phenyl) -estra-4,9-diene Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003862 glucocorticoid Substances 0.000 abstract 1
- 238000013160 medical therapy Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical group [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0081—Substituted in position 17 alfa and 17 beta
- C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
- C07J1/0096—Alkynyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/006—Ketals at position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Derivados de 16-hidroxi-11-(fenilo substituido)-estra-4,9-dieno de acuerdo con la formula (I), donde R1 es C1-6 alquil, C3-6 cicloalquil, C1-6alcoxi, triflato, piridil o fenilo donde la parte de fenilo opcionalmente se substituye por unoo más substituyentes seleccionados entre ciano, halogeno yC1-4alquil; R2 es hidrogeno, C1-6alquil, 1-oxo-C1-6 alquil o carboxi-1-oxo- C1-6 alquil; R3 es hidrogeno, halogeno o C1-6 alquil opcionalmente substituidopor uno o más substituyentesselec cionados entre C1-6 alcoxi y halogeno; R4 es hidrogeno, C1-6 alquil, 1-oxo-C1-6 alquil o carboxi-1-oxo-C1-6 alquil; yX es (H, OH), O o NOH; o una sal o solvato farmacéuticamente aceptable del mismo; un procedimiento de preparacion,formulacione s farmacéuticas que loscontienen y su uso en terapia médica, en particular en el tratamiento o profilaxis de enfermedades o síntomas glucocorticoide dependientes; y uncompuesto utilizable como intermediario para preparar a estosderivados.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97200098 | 1997-01-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR011409A1 true AR011409A1 (es) | 2000-08-16 |
Family
ID=8227931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980100151A AR011409A1 (es) | 1997-01-15 | 1998-01-14 | Derivados de 16-hidroxi-11-(fenil substituido)-estra-4,9-dieno, su utilizacion, un procedimiento para prepararlos, formulaciones farmaceuticasque comprenden a dichos derivados, y un compuesto utilizable como intermediario para prepararlos |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6072068A (es) |
| EP (1) | EP0973792B1 (es) |
| JP (1) | JP2001508079A (es) |
| KR (1) | KR20000070149A (es) |
| CN (1) | CN1248262A (es) |
| AR (1) | AR011409A1 (es) |
| AT (1) | ATE248854T1 (es) |
| AU (1) | AU736064B2 (es) |
| BR (1) | BR9807079A (es) |
| CA (1) | CA2277924A1 (es) |
| DE (1) | DE69817792T2 (es) |
| HU (1) | HUP0000901A3 (es) |
| ID (1) | ID22228A (es) |
| IL (1) | IL122740A (es) |
| NO (1) | NO313386B1 (es) |
| NZ (1) | NZ336790A (es) |
| PL (1) | PL334518A1 (es) |
| RU (1) | RU2187510C2 (es) |
| TR (1) | TR199902367T2 (es) |
| TW (1) | TW518339B (es) |
| WO (1) | WO1998031702A1 (es) |
| ZA (1) | ZA9884B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ514465A (en) * | 1999-04-30 | 2003-11-28 | Pfizer Prod Inc | Glucocorticoid receptor modulators |
| US6740645B1 (en) | 1999-09-03 | 2004-05-25 | Research Triangle Institute | 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties |
| DE19961219A1 (de) * | 1999-12-15 | 2001-07-19 | Jenapharm Gmbh | 11beta-Phenylestratrien-Derivate mit Fluoralkylgruppen in der aromatischen Seitenkette, deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| US7713989B2 (en) | 2000-04-27 | 2010-05-11 | Dow Robert L | Glucocorticoid receptor modulators |
| IL146057A (en) * | 2000-10-27 | 2007-09-20 | Pfizer Prod Inc | A process for the preparation of modulators of a non-steroidal glucocorticoid receptor |
| JP2002193911A (ja) * | 2000-10-28 | 2002-07-10 | Pfizer Prod Inc | グルココルチコイドレセプターモジュレーター |
| ES2246292T3 (es) | 2000-10-30 | 2006-02-16 | Pfizer Products Inc. | Moduladores de receptor glucocorticoide. |
| US7250408B2 (en) * | 2002-12-16 | 2007-07-31 | Bayer Schering Pharma Ag | Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility |
| KR101107949B1 (ko) | 2007-02-02 | 2012-02-08 | 화이자 프로덕츠 인코포레이티드 | 트라이사이클릭 화합물 및 글루코코르티코이드 수용체 조절자로서의 이들의 용도 |
| RU2326673C1 (ru) * | 2007-02-27 | 2008-06-20 | ФГУ Национальный научный центр наркологии Росздрава | ПРИМЕНЕНИЕ 17α-АЦЕТАТ-21-ПИВАЛОАТ 17α,21-ДИГИДРОКСИПРЕГН-4-ЕН-3,20-ДИОНА В КАЧЕСТВЕ СРЕДСТВА, СНИЖАЮЩЕГО ПАТОЛОГИЧЕСКОЕ ВЛЕЧЕНИЕ К КОКАИНУ |
| JP6196302B2 (ja) | 2012-07-10 | 2017-09-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | ３−置換エストラ−１，３，５（１０），１６−テトラエン誘導体、その調製法、これらを含む医薬製剤および医薬を調製するためのその使用 |
| SG11201505875WA (en) | 2013-02-21 | 2015-09-29 | Bayer Pharma AG | Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (akr1 c3) |
| CN113559075A (zh) | 2014-11-17 | 2021-10-29 | 康泰科思特生物制药公司 | 奥那司酮延长释放组合物和方法 |
| BR112018005999A2 (pt) | 2015-09-25 | 2019-01-08 | Context Biopharma Inc | métodos para a produção de intermediários de onapristona |
| KR20180113988A (ko) | 2015-12-15 | 2018-10-17 | 컨텍스트 바이오파마 인코포레이티드 | 비정질 오나프리스톤 조성물 및 그 제조방법 |
| EP3394079A4 (en) * | 2015-12-23 | 2019-08-21 | Oric Pharmaceuticals, Inc. | INHIBITORS OF GLUCOCORTICOIDREZEPTORS |
| US11110103B2 (en) | 2015-12-23 | 2021-09-07 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| EP3394078A4 (en) * | 2015-12-23 | 2019-11-27 | Oric Pharmaceuticals, Inc. | INHIBITORS OF THE GLUCOCORTICIDE RECEPTOR |
| CN106397519A (zh) * | 2016-08-30 | 2017-02-15 | 天津市中升挑战生物科技有限公司 | 一种烯丙孕素的制备方法 |
| DK3523315T3 (da) * | 2016-10-07 | 2021-05-03 | Oric Pharmaceuticals Inc | Inhibitor af glucocorticoidreceptor |
| US20180148471A1 (en) | 2016-11-30 | 2018-05-31 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
| CA3125151A1 (en) * | 2018-12-28 | 2020-07-02 | Panda Consulting Llc | Short-acting selective glucocorticoid receptor modulators |
| WO2023000135A1 (en) * | 2021-07-19 | 2023-01-26 | Context Biopharma Inc. | Processes of making onapristone and intermediates thereof |
| CN114456223B (zh) * | 2022-01-24 | 2023-07-21 | 湖南科益新生物医药有限公司 | 3-缩酮的合成方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2522328B1 (fr) * | 1982-03-01 | 1986-02-14 | Roussel Uclaf | Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments |
| NZ214998A (en) * | 1985-02-07 | 1989-06-28 | Schering Ag | 13-(methyl or ethyl)-11-beta-phenyl-gonane derivatives; preparatory processes and pharmaceutical compositions |
-
1997
- 1997-12-24 IL IL12274097A patent/IL122740A/xx active IP Right Grant
-
1998
- 1998-01-06 ZA ZA9884A patent/ZA9884B/xx unknown
- 1998-01-12 TW TW087100392A patent/TW518339B/zh not_active IP Right Cessation
- 1998-01-13 ID IDW990700A patent/ID22228A/id unknown
- 1998-01-13 EP EP98906887A patent/EP0973792B1/en not_active Expired - Lifetime
- 1998-01-13 CA CA002277924A patent/CA2277924A1/en not_active Abandoned
- 1998-01-13 WO PCT/EP1998/000377 patent/WO1998031702A1/en not_active Ceased
- 1998-01-13 PL PL98334518A patent/PL334518A1/xx unknown
- 1998-01-13 AU AU62935/98A patent/AU736064B2/en not_active Ceased
- 1998-01-13 JP JP53369598A patent/JP2001508079A/ja active Pending
- 1998-01-13 DE DE69817792T patent/DE69817792T2/de not_active Expired - Fee Related
- 1998-01-13 KR KR1019997006375A patent/KR20000070149A/ko not_active Ceased
- 1998-01-13 NZ NZ336790A patent/NZ336790A/en unknown
- 1998-01-13 RU RU99118008/04A patent/RU2187510C2/ru not_active IP Right Cessation
- 1998-01-13 CN CN98802618A patent/CN1248262A/zh active Pending
- 1998-01-13 TR TR1999/02367T patent/TR199902367T2/xx unknown
- 1998-01-13 BR BR9807079-7A patent/BR9807079A/pt not_active IP Right Cessation
- 1998-01-13 HU HU0000901A patent/HUP0000901A3/hu unknown
- 1998-01-13 US US09/341,603 patent/US6072068A/en not_active Expired - Fee Related
- 1998-01-13 AT AT98906887T patent/ATE248854T1/de not_active IP Right Cessation
- 1998-01-14 AR ARP980100151A patent/AR011409A1/es not_active Application Discontinuation
-
1999
- 1999-07-14 NO NO19993459A patent/NO313386B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0000901A3 (en) | 2001-07-30 |
| DE69817792T2 (de) | 2004-07-01 |
| NO993459D0 (no) | 1999-07-14 |
| TW518339B (en) | 2003-01-21 |
| NO313386B1 (no) | 2002-09-23 |
| RU2187510C2 (ru) | 2002-08-20 |
| HUP0000901A2 (hu) | 2000-10-28 |
| NO993459L (no) | 1999-09-07 |
| EP0973792A1 (en) | 2000-01-26 |
| ATE248854T1 (de) | 2003-09-15 |
| IL122740A0 (en) | 1998-08-16 |
| ID22228A (id) | 1999-09-23 |
| KR20000070149A (ko) | 2000-11-25 |
| WO1998031702A1 (en) | 1998-07-23 |
| ZA9884B (en) | 1998-07-08 |
| AU736064B2 (en) | 2001-07-26 |
| TR199902367T2 (xx) | 2000-04-21 |
| US6072068A (en) | 2000-06-06 |
| NZ336790A (en) | 2000-06-23 |
| IL122740A (en) | 2003-09-17 |
| AU6293598A (en) | 1998-08-07 |
| EP0973792B1 (en) | 2003-09-03 |
| BR9807079A (pt) | 2000-04-18 |
| PL334518A1 (en) | 2000-02-28 |
| JP2001508079A (ja) | 2001-06-19 |
| CN1248262A (zh) | 2000-03-22 |
| CA2277924A1 (en) | 1998-07-23 |
| DE69817792D1 (de) | 2003-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR011409A1 (es) | Derivados de 16-hidroxi-11-(fenil substituido)-estra-4,9-dieno, su utilizacion, un procedimiento para prepararlos, formulaciones farmaceuticasque comprenden a dichos derivados, y un compuesto utilizable como intermediario para prepararlos | |
| ES2055860T3 (es) | Derivados 2-aminopirimidinona. | |
| ES2145922T3 (es) | Compuestos espiro-azabiciclicos utiles en terapia. | |
| ES2100151T3 (es) | Nuevos derivados de benzopirano, procedimientos para su preparacion y su uso y composiciones que contienen los compuestos. | |
| NO20025821L (no) | 2-aminokarbonyl-9H-purinderivater | |
| NO20021328L (no) | Pyrazolopyrimidier som terapeutiske midler | |
| ES2186015T3 (es) | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol. | |
| CU22305A3 (es) | Procedimiento para la preparacion de un derivado de aminoacidos | |
| BR9916282A (pt) | Composto, uso de um um composto e método de tratamento | |
| EE05199B1 (et) | N-heterotsklilised derivaadid kui NOSi inhibiitorid | |
| ES2159591T3 (es) | Composicion de liberacion controlada. | |
| NO20073357L (no) | 5-karboksamid substituerte tiazol derivater som reagerer med ionekanaler, i saerdeleshet med ionekanaler fra Kv familien | |
| DK611686A (da) | Pyrazolinderivater, fremgangsmaade til fremstilling deraf og deres anvendelse som middel med insekticid og akaricid virkning | |
| UY29087A1 (es) | Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico | |
| ES2052603T3 (es) | Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen. | |
| ES2042711T3 (es) | Un procedimiento para preparar un compuesto quimico. | |
| BR9807950A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto | |
| NO971625L (no) | Nye peptider med immunomodulatoriske effekter | |
| NO20050664L (no) | 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer | |
| MX2024015922A (es) | Degradadores de proteinas del factor 2 relacionado con el eritroide de factor nuclear 2 (nrf2) | |
| EA200500882A1 (ru) | N-арилсульфонил-3-аминоалкоксииндолы | |
| SE7608092L (sv) | Nya steroider | |
| AR002260A1 (es) | Compuestos derivados de acido [4-(indazol-3-il)-piperidin-1-il]-acetico, procedimiento para su preparacion, composicion farmacuetica que los contienen,el uso de los mismos en la preparacion de un agente terapeutico, metodo de tratamiento y compuestos intermediarios. | |
| DK0634396T3 (da) | Aminosyrederivater og deres anvendelse som enkeltfalinaseinhibitorer | |
| ES452601A1 (es) | Procedimiento para la preparacion de nuevos derivados pipe- ridinicos tetraciclicos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |